Sign In
to Vote &
Create Storyboards.
 
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, has announced new data on extending the serum half-life of albumin in vivo. This compelling data set, recently presented at PepTalk 2014, demonstrates the potential of the company's half-life extension platform to deliver greater control of the therapeutic half-life of drug candidates, while showing how the technology can introduce the possibility for monthly dosing.
0
0
0


Storyboard
Print
Share this Article

Recommended

  • {TITLE}
    {PUBLISHER} - {PUBLISHED_DATE}
    {VIEWS}
  • Create Storyboard